Cardiovascular safety of empagliflozin in patients with Type 2 diabetes: a metaanalysis of placebo-controlled trials

被引：0
|
作者：
Salsali, A. [1 ]
Kim, G. [2 ]
Woerle, H. J. [2 ]
Broedl, U. C. [2 ]
Hantel, S. [3 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, Diabet Clin Res, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Med IA Metab, Ingelheim, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany
来源：
DIABETIC MEDICINE | 2017年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A74
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
    Salsali, A.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    Hantel, S.
    DIABETES OBESITY & METABOLISM, 2016, 18 (10): : 1034 - 1040
  • [2] Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
    Tuttle, Katherine R.
    Levin, Adeera
    Nangaku, Masaomi
    Kadowaki, Takashi
    Agarwal, Rajiv
    Hauske, Sibylle J.
    Elsasser, Amelie
    Ritter, Ivana
    Steubl, Dominik
    Wanner, Christoph
    Wheeler, David C.
    DIABETES CARE, 2022, 45 (06) : 1445 - 1452
  • [3] Safety and tolerability of empagliflozin in patients with type 2 diabetes and advanced kidney disease: a large pooled analysis of placebo-controlled trials
    Levin, A.
    Nangaku, M.
    Kadowaki, T.
    Tuttle, K.
    Hauske, S.
    Zeller, C.
    Kohler, S.
    von Eynatten, M.
    Wanner, C.
    DIABETOLOGIA, 2017, 60 : S85 - S85
  • [4] Placebo-controlled trials in type 2 diabetes
    Misbin, RI
    DIABETES CARE, 2001, 24 (04) : 773 - 774
  • [5] Comment on the ethics of placebo-controlled trials in patients with type 2 diabetes mellitus
    Misbin, RI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02): : 823 - 823
  • [6] Ethics of placebo-controlled trials in patients with type 2 diabetes mellitus - Response
    Fonseca, V
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02): : 823 - 824
  • [7] Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study
    Thiele, Kirsten
    Rau, Matthias
    Hartmann, Niels-Ulrik K.
    Moellmann, Julia
    Jankowski, Joachim
    Boehm, Michael
    Keszei, Andras P.
    Marx, Nikolaus
    Lehrke, Michael
    DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2814 - 2818
  • [8] Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with Type 2 diabetes: pooled data from four randomised, placebo-controlled phase III trials
    Hach, T.
    Gerich, J.
    Salsali, A.
    Kim, G.
    Hantel, S.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2014, 31 : 64 - 65
  • [9] Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study
    Rau, Matthias
    Thiele, Kirsten
    Hartmann, Niels-Ulrik Korbinian
    Moellmann, Julia
    Wied, Stephanie
    Boehm, Michael
    Scharnagl, Hubert
    Maerz, Winfried
    Marx, Nikolaus
    Lehrke, Michael
    ATHEROSCLEROSIS, 2021, 330 : 8 - 13
  • [10] Short-term effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular diseases: a placebo-controlled randomised trial (EMBLEM)
    Tanaka, A.
    Shimabukuro, M.
    Machii, N.
    Teragawa, H.
    Okada, Y.
    Shima, K. R.
    Takamura, T.
    Taguchi, I.
    Hisauchi, I.
    Sato, Y.
    Ueda, S.
    Higashi, Y.
    Node, K.
    DIABETOLOGIA, 2019, 62 : S560 - S561
12345